ERRATA

This comprehensive review explores the evolving role of surgery in the management of Primary Central Nervous System Lymphoma (PCNSL), a rare and aggressive form of non-Hodgkin lymphoma confined to the CNS. Historically, surgical intervention has been limited to diagnostic biopsy due to the tumor's diffuse nature and sensitivity to chemotherapy. However, recent advances in neurosurgical techniques and molecular profiling have prompted a reevaluation of surgery's role in PCNSL treatment. This review highlights the potential benefits of surgery in specific cases, such as solitary lesions with significant mass effect or failure of non-invasive diagnostics. It further discusses the integration of surgery with high-dose methotrexate-based chemotherapy and radiotherapy, emphasizing that while surgery may not offer survival benefits in most cases, it can alleviate life-threatening symptoms and enhance treatment efficacy in selected patients. The results suggest that although surgery remains adjunctive to chemotherapy, careful patient selection and advancements in minimally invasive techniques could improve outcomes in well-defined clinical scenarios. Further research is needed to optimize multimodal approaches and refine surgical indications.